T-Track® CMV
ELISpot-assay for monitoring the functionality of CMV-specific cell-mediated immunity (CMI) in CMV-seropositive patients.
Infections with human cytomegalovirus (CMV, HHV5) normally cause only mild disease symptoms, and many patients even remain asymptomatically. However, immunocom-promised patients, e.g. therapeutically induced after transplantation, are at high risk for serious damage due to CMV-infections. Under immunosuppressive conditions, CMV infection or reactivation can cause a severe clinical course of disease.
T-Track® CMV is a standardized, highly sensitive and reliable in vitro diagnostic (IVD) test for monitoring the functionality of CMV-specific cell-mediated immunity. The ELISpot-technology-based T-Track® CMV was developed to identify groups of patients at increased risk for CMV-related clinical complications and to improve individual CMV management. Using Mikrogens’ (formerly Lophius Bioscience) patented T-activation technology, T-Track® CMV detects IFN-γ secretion from the broad network of clinically relevant CMV-reactive effector cells, allowing a se-miquantitative assessment of CMV-specific immunocompetence. The test is not suitable to detect a CMV infection.
To support your antiviral therapy decisions, results from the all-in-one T-Track® CMV ELISpot kit can be obtained and analyzed in diagnostic laboratories within 24 hours.
T-Track® CMV: T-cell diagnostics for individual therapy decisions
- CE-marked IVD (in vitro diagnostic product) – IFN-γ ELISpot
- Supporting antiviral therapy decisions (risk stratification)
- Assessment of CMV-specific immune response and reconstitution
- Measurement of the functionality of CD8+ cells, CD4+ cells and NK cells as well as NKT-like cells and antigen-presenting cells (APC)
- Highly sensitive and standardized immune monitoring tool
- Optimized, user-friendly protocol
- HLA-independent application
- Evaluation with T-Track® CMV Calculator software (Article number: 11071001, free of charge) recommended
